By DEEKSHA HEGDE
I had an itch to attract parallels between the 2. The structural info saved lining up in methods I couldn’t dismiss, and by the top, I ended making an attempt.
Operate’s product is an app: you pay $365 a yr, go to a Quest Diagnostics location, get 160+ biomarkers examined twice a yr, and obtain clinician-written notes deciphering your outcomes. The lab testing is totally outsourced. Operate is the layer on prime: panel design, member expertise, clinician observe technology, longitudinal monitoring.
Operate Well being raised $298 million at a $2.5 billion valuation in November 2025. At 25x income, the market clearly isn’t shopping for a lab reseller. It’s shopping for the information flywheel: longitudinal biomarker histories that compound in scientific worth over time, aggregated throughout tons of of 1000’s of members right into a dataset that well being plans, pharma corporations, and AI builders can’t construct every other approach. A member with 4 years of information can’t swap to a less expensive competitor with out shedding the pattern. The unit economics work if the interpretation layer scales with out proportionally scaling headcount, which is what the Medical Intelligence Lab, their generative AI mannequin launched in November 2025, is constructed to do. Operate can also be constructing towards a B2B enterprise channel, positioning the product as a option to maintain workers “wholesome, targeted, and able to carry out.”
It satisfies a burning want for particular personas: the nervous properly, the well being optimizers, the individuals who noticed their family members get identified just a little too late, the individuals who aren’t ready for a analysis earlier than they begin paying consideration. These are individuals the remainder of the business has principally left alone. I wrote earlier this yr, in a bit on Hinge Well being, concerning the prevention paradox: the employer ROI mannequin is structurally blind to the member who advantages most from early intervention. Operate skips the employer ROI story fully, expenses the member instantly, and doesn’t attempt to show a CFO case it will possibly’t make. But.
Take apoB, quick for apolipoprotein B, one in all Operate’s most prominently marketed biomarkers, a greater predictor of cardiovascular danger than the LDL check most annual physicals nonetheless depend on. The Swedish AMORIS cohort examine adopted 137,000 individuals for a median of 17.8 years and located that elevated apoB separates circumstances from controls roughly 20 years earlier than a serious cardiovascular occasion, with the hole sharpening over the last decade closest to the occasion. Catch it, act on it — statins, dietary modifications, nearer monitoring — and you would forestall a coronary heart assault. That’s actual scientific worth.
Now run the employer math. Median personal sector tenure in the US is 3.5 years. The employer funding the Operate membership will nearly definitely not be insuring this particular person when that cardiovascular occasion materializes. The prevented price accrues to whoever covers them in fifteen years. The CFO writing the test as we speak captures none of it. What Operate is definitely promoting proper now to employers is a wellness perk. Higginbotham, an insurance coverage dealer, introduced a partnership in January 2026 providing Operate to workers at $334 as an alternative of $365. A $31 low cost. You don’t construct a $2.5 billion firm on a fitness center stipend.
What well being plans and pharma companions would really pay for doesn’t exist but: actuarial danger fashions and analysis datasets constructed on years of longitudinal biomarker knowledge at scale. The D2C subscription is the information acquisition engine for that product. Every little thing depends upon the flywheel operating lengthy sufficient to shut the hole.
That’s the place the 23andMe comparability clicked for me.
23andMe was a D2C well being knowledge firm whose valuation rested on a knowledge monetization thesis: pharma analysis partnerships, knowledge licensing. Package gross sales alone couldn’t justify it. It wasn’t a HIPAA-covered entity, and it collected delicate well being knowledge below a privateness coverage that reserved the best to switch it in a sale or chapter. The patron advertising and marketing, although, by no means stated any of this. 23andMe led with ancestry, which made it viral, emotionally sticky, and FDA-adjacent fairly than FDA-regulated. Well being reviews had been the upsell. “Contributing to science” was how they framed knowledge acquisition: altruism, not a transaction. The GSK partnership ($300 million for analysis entry to the genetic database) was disclosed within the phrases of service, for the individuals who learn the tremendous print. When the enterprise failed, the information was a sellable asset, and Regeneron grabbed it in a storage sale.
Operate is structurally related, with increased stakes on each dimension. D2C well being knowledge firm, knowledge monetization thesis: enterprise danger fashions, analysis partnerships, AI. Additionally not a HIPAA-covered entity. It doesn’t invoice insurance coverage and isn’t a lined healthcare supplier, which suggests the authorized protections most members assume apply to their well being knowledge don’t. The identical chapter switch loophole that caught 23andMe’s members would catch Operate’s too.
23andMe’s income mannequin was damaged from day one: purchase a package as soon as, finished. Operate has recurring subscriptions and actual switching prices. 23andMe additionally imploded making an attempt to turn out to be a therapeutics firm, a pivot that required capabilities fully overseas to what it had. Operate’s monetization path is not less than adjoining to what it already does.
However the regulatory publicity is similar, and that window is closing. The FTC up to date its Well being Breach Notification Rule in April 2024, explicitly extending it to well being apps and D2C platforms, and has already used it in opposition to GoodRx, Premom, and BetterHelp. HIPRA, the Well being Data Privateness Reform Act launched in November 2025, would prolong HIPAA-equivalent obligations to precisely the class of firm Operate is.
The info Operate holds makes this publicity worse. 23andMe held genetic predisposition knowledge: probabilistic, future-oriented, a danger modifier. Operate’s biomarker knowledge is present: thyroid operate, metabolic standing, hormonal profile, cardiovascular markers, up to date twice a yr. Extra actionable, extra temporally exact, extra instantly helpful to anybody making selections based mostly in your well being.
Which ends up in an issue Operate hasn’t totally named. Their D2C model runs on a selected promise: your knowledge is yours, and we’re serving to you perceive it. That’s what acquired 200,000 members. 23andMe acquired its first tens of millions the identical approach, utilizing aspirational id advertising and marketing to seize knowledge property, whereas the precise worth creation required a B2B transaction that the buyer advertising and marketing by no means ready the person for. Operate’s member base skews extra refined than 23andMe’s ever did — these are individuals who already consider their knowledge has scientific worth. Operate’s advertising and marketing hasn’t constructed the narrative structure but to ask them right into a transaction they’re already in.
The playbook exists. Oura selected the NBA and UCSF as analysis companions. These are establishments that made members really feel like members in one thing elite and scientific. Whoop publishes findings utilizing mixture member knowledge. In each circumstances, the identical underlying knowledge transaction reads as an identity-enhancing contribution as a result of the framing was constructed into the model from the beginning, not buried within the phrases of service. Operate’s biomarker knowledge is extra clinically delicate than wearable knowledge like HRV and sleep levels, and its B2B thesis extra load-bearing, which suggests the identical playbook wants extra rigor in execution. Companion choice is model work: the primary disclosed analysis partnerships will set the body for all the things. Publishing findings normalizes the information relationship whereas constructing the product validity case Operate wants earlier than well being plans will write a test.
Operate is already executing on elements of this playbook — the NBPA partnership in February 2026 brings biomarker testing to skilled athletes, and the model sign is actual. However a distribution deal isn’t a analysis relationship. What’s lacking is analysis partnerships structured to supply and publish findings, the sort that flip distribution into proof, and proof into retention.
There’s one other layer that neither Oura nor Whoop has constructed. Proactive knowledge governance is what makes the contribution framing credible fairly than simply model copy. Operate presently describes itself as “HIPAA-aligned”, following key necessities of the Safety Rule voluntarily. That’s the hole in a single phrase. Safety practices with out authorized dedication don’t shut the chapter switch loophole, don’t fulfill IRB consent necessities for future pharma companions, and don’t give insurance coverage companions the peace of mind they should license a dataset with out importing regulatory publicity. Adopting HIPAA-equivalent knowledge dealing with earlier than HIPRA passes and framing it as a product choice fairly than a compliance response protects the flywheel from being dismantled earlier than it matures.
Operate has a window to behave by itself phrases. 23andMe waited for regulators to put in writing the principles and have become the cautionary story these guidelines had been named after. Operate might write the playbook as an alternative.
Deeksha Hegde is a bioengineer who writes about healthtech and digital well being positioning on Substack.
